Jyong Biotech (MENS) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MacroGenics (MGNX) has outperformed Jyong Biotech (MENS) over the past year, gaining 40.0% versus a loss of 95.3%. MacroGenics is the larger company by market cap ($125.3 million vs $110.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | MGNX |
|---|---|---|
| Share price | $1.45 | $1.96 |
| Market cap | $110.24M | $125.26M |
| 1-day change | -17.14% | -1.01% |
| YTD return | -63.29% | +21.74% |
| 1-year return | -95.28% | +40.00% |
| 5-year return | — | -89.56% |
| EPS (TTM) | $-0.06 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $149.50M |
| Revenue growth (YoY) | — | -0.31% |
| Net income (latest FY) | $-4.67M | $-74.62M |
| Gross margin | — | 100.00% |
| Operating margin | — | -48.72% |
| Net margin | — | -49.91% |
| 52-week high | $38.88 | $5.08 |
| 52-week low | $1.43 | $1.32 |
| Distance from 52-week high | -96.27% | -61.42% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +308.16% |
| Average volume | 44.23K | 747.02K |
| Shares outstanding | 74.23M | 63.91M |
| Employees | 27 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed MENS by 135.3 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
MENS vs MGNX FAQ
Which is bigger, Jyong Biotech or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $110.24M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or MGNX?
MGNX returned +40.00% over the past 12 months, compared with -95.28% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.